# Trade Mark Journal No.2026/021 22 May 2026

## WO0000001916229 (5,40,42)

Office of origin: United States of America

Date of International Registration:24 February 2026
Date of designation in the UK: 24 February 2026

The mark consists of a squiggly design element to the left of the word "callio" that is above the word "THERAPEUTICS".

International priority date claimed: 26 August 2025 (United States of America) (99357982)

Class 5
  Pharmaceutical and biological preparations; pharmaceuticals and biological preparations for prophylactic, diagnostic, and therapeutic use in treating, preventing, and managing cancer; therapeutic agents for medical use, namely, proteins and derivatives, antibody-drug conjugates, immunostimulatory antibody-drug conjugates, antibodies with multiple drug or cytokine conjugates, multispecific antibodies, and engineered antibodies; pharmaceutical and biological preparations for the prevention, diagnosis and treatment of diseases for scientific, clinical, medicinal, therapeutic and diagnostic purposes; pharmaceutical and biological preparations for use in oncology.
Class 40
  Custom manufacturing of pharmaceuticals and therapeutic agents for medical use.
Class 42
  Research and development in the fields of pharmaceuticals, biologics, chemistry, protein engineering, proteins and derivatives, antibody-drug conjugates, immunostimulatory antibody-drug conjugates, antibodies with multiple drug or cytokine conjugates, multispecific antibodies, and engineered antibodies, oncology; providing medical scientific research information in the fields of pharmaceuticals, biologics, chemistry, protein engineering, proteins and derivatives, antibody-drug conjugates, immunostimulatory anti-drug conjugates, antibodies with multiple drug or cytokine conjugates, multispecific antibodies, and engineered antibodies, oncology, and immunology; drug discovery, custom design, and development services featuring therapeutic agents for the treatment and prevention of diseases; scientific investigations for medical purposes featuring clinical trials.

Callio Operating Co, Inc.

Representative: Joyce Liou Morrison & Foerster LLP, 425 Market Street, Suite #3200, San Francisco CA 94105, UNITED STATES OF AMERICA